Statement: At least one participant of the primary trial died in under a 100 days.
Primary_evidence: Outcome Measurement:    Progression Free Survival (PFS)   Progression free survival is defined as time from date of registration until the date of first documented disease progression or date of death from any cause, whichever occurs first.   Time frame: From date of registration until disease progression or death, whichever occurs first Results 1:    Arm/Group Title: Avastin (Bevacizumab) Plus Hormone   Arm/Group Description: All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.   Overall Number of Participants Analyzed: 30   Median (95% Confidence Interval)   Unit of Measure: days  125.5        (90 to 256)